Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rande Is. . .FISHING. . [under $1.50] -- Ignore unavailable to you. Want to Upgrade?

To: Rande Is who wrote (1577)	3/30/1999 8:57:00 AM
From: Bucky Katt	Read Replies (1) \| Respond to of 4766

We all agree, QQQ is hip. Now, where will the next big thing be, years down the road? Maybe biotech, here is why> WHILE potent chemotherapy drugs are extremely successful at killing tumors in their early stages, they often fail when patients need them most — after their cancers have spread. And for years, no one understood why. Several years ago, scientists at the University of North Carolina at Chapel Hill discovered the answer. And now, they have found a way to overcome the problem. At the root of the problem: a protein known as NF-kappa B that attaches to DNA inside the nucleus of cells and acts as a switch to turn genes on and off. In cancer, it is an extremely cunning. Instead of being inhibited by potent cancer drugs, it is activated by them. So just when the drugs are supposed to be doing their work of killing off tumor cells, NF-kappa B kicks in and sends out a survival signal. Not only do the tumor cells escape death, but they continue reproducing. The cancer spreads, often killing. “They are like Star Trek-type shields,” says study author Albert S. Baldwin Jr., an associate professor of biology. “They are a front-line defense that tumor cells put up when exposed to chemotherapy that makes them resistant to the drugs' effects.” Not to be outfoxed by a protein, the North Carolina researchers hit upon a brilliant idea: Why not block its action? Early results indicate the strategy is working. Using a natural inhibitor protein known as I-kappa, the team successfully blocked NF-kappa B in mice with human tumors. Not only did the cancer cells continue to be susceptible to chemotherapy, but in some cases, they disappeared altogether following treatment, Baldwin says. Working on some small cap picks, with very high risk/reward ratios.